Thomas Kosasa, serving as a director and significant 10% owner within OneMedNet Corp (NASDAQ:ONMD), finalized an acquisition of 158,730 shares of the company's common stock on June 12, 2026. The transaction, valued at approximately $99,999, was executed at a price of $0.63 per share. This purchase price stands in contrast to the stock's current trading level of $0.54, which reflects a 21% decline over the past week, indicating that Mr. Kosasa's acquisition was executed at a premium relative to recent market valuations.
The transaction was structured pursuant to a formal subscription agreement established between the issuer and Mr. Kosasa, facilitating a $100,000 investment in the company. To determine the share valuation, the agreement utilized the volume-weighted average price of OneMedNet stock over the ten trading days immediately preceding the purchase date. Following this acquisition, Mr. Kosasa's direct holdings in OneMedNet common stock total 17,088,874 shares.
This insider purchase occurs against a backdrop of reported financial adjustments for the medical technology firm. InvestingPro rates the company's overall financial health as "WEAK," with 13 additional ProTips available to subscribers detailing key risks and opportunities associated with the organization. Despite this rating, OneMedNet Corporation has reported a significant 329% increase in revenue, reaching $1.25 million in 2025, compared to $292,000 in 2024. Furthermore, the company announced a reduction in liabilities by 74%, decreasing from $19.7 million at the end of 2024 to $5.1 million at the end of 2025.
Looking ahead, OneMedNet has secured over $3 million in bookings for 2026, surpassing the total bookings for 2025. These bookings are expected to be recognized as revenue by the end of the third quarter of 2026. In other developments, OneMedNet received a notice from the Nasdaq Listing Qualifications Department regarding non-compliance with the minimum bid price requirement. The company has until October 12, 2026, to regain compliance by maintaining a minimum bid price of $1.00 per share for ten consecutive business days. Additionally, OneMedNet has entered into a collaboration with Inka Health to provide access to its iRWD platform for oncology data. This partnership is intended to aid in the development of Onco-Innovations' cancer treatment technology.
Market data indicates that ONMD closed at 0.5435 on 12/06, reflecting a decrease of -0.0409 (-7.00%). Pre-market activity shows a price of 0.55, an increase of +0.0065 (+1.20%) as of 06:09:38. The stock's performance over various timeframes, including 1D, 1W, 1M, 6M, 1Y, 5Y, and Max, highlights the volatility surrounding the security.